BHCM
ELDN icon

Brevan Howard Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Brevan Howard Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
304,707
+76,150
+33% +$277K 0.01% 982
2026
Q1 		$680K Buy
228,557
+32,800
+17% +$77.3K 0.01% 1116
2025
Q4 		$286K Buy
+195,757
New +$465K ﹤0.01% 1398
2025
Q2 		– Sell
-12,080
Closed -$41K – 1883
2025
Q1 		$41K Buy
+12,080
New +$49.7K ﹤0.01% 1099

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Brevan Howard Capital Management's ELDN Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Eledon Pharmaceuticals (ELDN) stake by 33% in Q2 2026, buying an estimated $277K and bringing the position to 304,707 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #982.

Brevan Howard Capital Management first reported a position in ELDN in Q1 2025 and has held it in 4 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Brevan Howard Capital Management held 304,707 shares of Eledon Pharmaceuticals worth $1.17M as of Q2 2026.
  • Brevan Howard Capital Management bought 76,150 Eledon Pharmaceuticals shares in Q2 2026, an estimated $277K.
  • Eledon Pharmaceuticals made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #982 holding.
  • Brevan Howard Capital Management first reported a position in Eledon Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.